Monitoring Vaccine Safety. Protecting Public Trust.
At Biovac, patient safety is at the heart of everything we do. Pharmacovigilance is the ongoing process of monitoring, detecting, assessing, and responding to any potential side effects or safety concerns related to vaccines.
Vaccines undergo rigorous clinical trials before approval. However, safety monitoring does not stop there. Continuous post-marketing surveillance ensures that vaccines remain safe and effective in real-world use.
Biovac is committed to maintaining the highest standards of safety monitoring in line with national and international regulatory requirements.
What is Pharmacovigilance?
Pharmacovigilance refers to the science and activities related to:
- Detecting and evaluating adverse events following immunisation (AEFIs)
- Monitoring vaccine safety throughout its lifecycle
- Reporting safety data to regulatory authorities
- Taking appropriate action where necessary
This process helps ensure that the benefits of vaccines continue to outweigh any potential risks.
Reporting a Side Effect or Safety Concern
If you are a healthcare professional, caregiver, or patient who wishes to report a suspected adverse event related to a Biovac product, please contact our Pharmacovigilance team, we request the below information:
- Details of the reporter (Request for Contact details and ask for
consent to be contacted by our Pharmacovigilance team for followup) - Patient details
- The Biovac Product details
- And the adverse event
The Pharmacovigilance mailbox drugsafety@biovac.co.za, within 24 hours after receiving all the required information
MeasBio Safety Information:
Below you will find safety information and reporting guidance related to
MeasBio.
[Download MeasBio DHCPL – 26 June 2023 ]
[Download MeasBio DHCPL – 31 March 2023]